MMP9 Antibody (YA7569)

MMP-9 (matrix metalloproteinase-9), also known as gelatinase B, is a zinc-dependent extracellular endopeptidase that mediates extracellular matrix remodeling through proteolytic cleavage of gelatin, type IV collagen, laminin, elastin, and additional matrix-associated substrates, thereby regulating tissue turnover, cell migration, and microenvironmental remodeling^[1][2]. Mechanistically, MMP-9 is synthesized as an inactive proenzyme and becomes activated through proteolytic removal of its prodomain, enabling participation in inflammatory signaling, leukocyte trafficking, angiogenesis, and tissue repair processes^[1][3]. MMP-9 also modulates biological activity of cytokines, chemokines, growth factors, and cell-surface signaling molecules, linking extracellular matrix degradation with immune and vascular responses^[3][4]. In disease settings, dysregulated or persistent MMP-9 expression is associated with cancer progression, invasion, metastasis, vascular remodeling, neuroinflammatory disorders, and blood-brain barrier disruption, making MMP-9 a widely studied pathogenic mediator and biomarker candidate^[3][5][6]. Compared with the closely related gelatinase MMP-2, MMP-9 displays distinct substrate preferences, inducible expression in inflammatory conditions, predominant storage in neutrophils, and primary inhibition by TIMP-1, whereas MMP-2 is generally constitutively expressed and preferentially regulated by TIMP-2^[4]. Structural differences, including a unique loop region and distinct regulatory mechanisms, further support functional separation between the two gelatinases in physiological and pathological remodeling^[2][4]. For experimental applications, MMP-9-selective inhibitors and neutralizing antibodies are widely used to investigate extracellular matrix remodeling, angiogenesis, inflammatory responses, and tumor progression, although achieving high selectivity remains a major challenge because of structural homology within the matrix metalloproteinase family^[5][7].